Skip to main content

Table 2 Clinicopathological factors

From: The effect of anastrozole on bone mineral density during the first 5 years of adjuvant treatment in postmenopausal women with early breast cancer

 

Number of patients (%)

T

 Tis

2 (3.6)

 T1

27 (49.1)

 T2

23 (41.8)

 T3

0 (0)

 T4b

3 (5.5)

N

 N0

47 (85.5)

 N1–2

8 (14.5)

Estrogen receptor

 Positive

54 (98.2)

 Negative

1 (1.8)

Progesterone receptor

 Positive

38 (69.1)

 Negative

17 (30.9)

HER2

 Positive

7 (12.7)

 Negative

45 (81.8)

 Unknown

3 (5.5)